Ravulizumab - Alexion Pharmaceuticals

Drug Profile

Ravulizumab - Alexion Pharmaceuticals

Alternative Names: ALXN 1210

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alexion Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action Complement C5 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria; Haemolytic uraemic syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
  • Phase I Immunological disorders

Most Recent Events

  • 01 Nov 2017 Ravulizumab - Alexion Pharmaceuticals receives Orphan Drug status for Haemolytic uraemic syndrome in USA, before November 2017
  • 26 Oct 2017 Alexion Pharmaceuticals plans a PK-based phase III trial for Paroxysmal nocturnal haemoglobinuria and Haemolytic uraemic syndrome (SC) in late 2018 (CTP#289760)
  • 31 Aug 2017 Phase-III clinical trials in Haemolytic uraemic syndrome (Treatment-naive, In infants, In adolescents, In children) in Belgium, United Kingdom, Spain, South Korea (unspecified route) (NCT03131219) (EudraCT2016-002499-29)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top